Precigen (PGEN)
NASDAQ:PGEN
PGEN Stock Chart & Stats
$3.67
-$0.11(-8.33%)
At close: 4:00 PM EST
$3.67
-$0.11(-8.33%)
Day’s Range― - ―
52-Week Range$1.11 - $5.47
Previous CloseN/A
Volume729.99K
Average Volume (3M)4.27M
Market Cap
$1.30B
Enterprise Value$1.08B
Total Cash (Recent Filing)$97.86M
Total Debt (Recent Filing)$5.12M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
May 11, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding353,928,680
10 Day Avg. Volume3,470,264
30 Day Avg. Volume4,265,436
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)60.91
Price to Sales (P/S)131.52
P/FCF Ratio-14.18
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue111.26
Enterprise Value/Gross Profit264.08
Enterprise Value/Ebitda-4.38
Forecast
1Y Price Target
$9.50Price Target Upside158.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$98.61M
Bulls Say, Bears Say
Bulls Say
FDA Full Approval & Durable DataFull FDA approval with a broad label and multi‑year durable response data materially lowers regulatory and adoption risk. Durable clinical outcomes and guideline endorsement help sustain demand, support formulary decisions, and shorten payer contracting timelines over the next 2–6 months.
Rapid Payer Access & Patient UptakeBroad payer coverage and quick hub growth indicate structural access to care and strong initial demand. High coverage reduces reimbursement friction and supports a sustainable commercial ramp, improving predictability of revenue conversion over coming quarters.
Near‑term Path To Cash‑flow BreakevenA defined runway to breakeven backed by tangible cash reserves and rising product revenues reduces near‑term dilution risk. If commercial uptake meets expectations, the company can fund scale‑up of sales and distribution without immediate large capital raises, stabilizing finances.
Bears Say
Elevated LeverageSharp increase in leverage meaningfully reduces financial flexibility and raises refinancing risk. A thinner equity cushion limits the company’s ability to absorb setbacks or fund further R&D/commercial expansion without incurring higher funding costs or dilution over the medium term.
Persistent Cash BurnConsistent negative operating and free cash flow implies reliance on external funding until commercial profits materialize. Ongoing cash burn increases the probability of future capital raises that could dilute shareholders and constrain investment in pipeline and commercialization if revenues disappoint.
Large Reported 2025 Net LossA very large reported loss, even with noncash components, signals elevated operating and financing strain and reduces retained capital. Combined with launch‑related cost increases, this weakens near‑term profitability resilience and heightens execution risk during the commercialization scale.
Precigen News
PGEN FAQ
What was Precigen’s price range in the past 12 months?
Precigen lowest stock price was $1.11 and its highest was $5.46 in the past 12 months.
What is Precigen’s market cap?
Precigen’s market cap is $1.30B.
When is Precigen’s upcoming earnings report date?
Precigen’s upcoming earnings report date is May 11, 2026 which is in 43 days.
How were Precigen’s earnings last quarter?
Precigen released its earnings results on Mar 25, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.084 by $0.014.
Is Precigen overvalued?
According to Wall Street analysts Precigen’s price is currently Undervalued.
Does Precigen pay dividends?
Precigen does not currently pay dividends.
What is Precigen’s EPS estimate?
Precigen’s EPS estimate is -0.03.
How many shares outstanding does Precigen have?
Precigen has 353,928,680 shares outstanding.
What happened to Precigen’s price movement after its last earnings report?
Precigen reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.084. Following the earnings report the stock price went up 25.484%.
Which hedge fund is a major shareholder of Precigen?
Currently, no hedge funds are holding shares in PGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precigen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.50 (158.86% Upside)
$9.50 (158.86% Upside)
Blogger Sentiment
Bullish
PGEN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.6%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Negative
20 days / 200 days
Momentum
123.78%
12-Months-Change
Fundamentals
Return on Equity
-8396.72%
Trailing 12-Months
Asset Growth
6.88%
Trailing 12-Months
Company Description
Precigen
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
PGEN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, tangible commercial momentum driven by full FDA approval and an accelerating launch: substantive payer coverage (≈215M lives, ~90% of insured lives), rapid growth in the patient hub (>300 patients), and an aggressive Q1 revenue expectation (> $18M) support a positive commercial inflection. These positives are balanced against large historical net losses ($429.6M in 2025), a significant SG&A increase (69.8%) tied to the launch, limited product revenue in 2025 due to a late-quarter start, and operational execution risks (conversion timing, EMA timeline, gross-to-net pressure). Overall, the highlights around product approval, payer uptake, and early demand materially outweigh the financial and operational challenges disclosed, leading to a constructive outlook for the company’s commercial transition.View all PGEN earnings summariesPGEN Stock 12 Month Forecast
Average Price Target
$9.50
▲(158.86% Upside)
Technical Analysis
MiMedx Group
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Immunome
―
Praxis Precision Medicines
―
Ownership Overview
37.38% Insiders
11.27% Mutual Funds
14.28% Other Institutional Investors
29.39% Public Companies and
Individual Investors